AVTR Stock Recent News

AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.

Avantor Inc AVTR reported in-line earnings for its first quarter on Friday.

Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio.

Avantor Inc AVTR on Friday reported adjusted EPS of 23 cents in line with consensus.

Avantor (AVTR) shares sank 16% Friday after the maker of lab chemicals and other life sciences products announced its CEO was resigning, reported weaker-than-expected net sales as government spending fell, and slashed its guidance.

Avantor, Inc. (NYSE:AVTR ) Q1 2025 Earnings Call April 25, 2025 8:00 AM ET Company Participants Allison Hosak - SVP of Global Communications and Brand Michael Stubblefield - President and CEO R. Brent Jones - EVP and CFO Conference Call Participants Michael Ryskin - Bank of America Securities Vijay Kumar - Evercore ISI Rachel Vatnsdal - J.P.

While the top- and bottom-line numbers for Avantor (AVTR) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.23 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.22 per share a year ago.

Board initiates search process to identify next CEO RADNOR, Pa. , April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor.

Net sales of $1.58 billion, decrease of 6%; organic decline of 2% Net income of $64.5 million; Adjusted EBITDA of $269.5 million Diluted GAAP EPS of $0.09; adjusted EPS of $0.23 Operating cash flow of $109.3 million; free cash flow of $82.1 million Announces significant actions across the business to accelerate growth and enhance cost structure; increasing cost transformation target to $400 million in gross run-rate savings exiting 2027 RADNOR, Pa. , April 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal quarter ended March 31, 2025.